在阿尔茨海默氏症疾病中的免疫激活
Arnaud Mary1, Renzo Mancuso2,3, Michael T Heneka1,4
1Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg;
Annual review of immunology
|February 29, 2024
概括
阿尔茨海默病 (AD) 涉及慢性免疫激活. 微质细胞,大脑免疫细胞,检测粉样β,并有助于AD的发病,突出显示免疫系统在神经退行过程中的作用.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种主要的神经退行性疾病,负担越来越大.
- 传统上与粉样β (Aβ) 斑块和团有关,慢性免疫激活现在被认为是AD发病的关键因素.
- 了解免疫系统的作用对于开发有效的AD治疗至关重要.
研究的目的:
- 审查了解阿尔茨海默病免疫激活的最新进展.
- 探索微质和外周信号在阿尔茨海默病的发病过程中的作用.
- 在AD的背景下讨论研究人类微质细胞的策略.
主要方法:
- 关于阿尔茨海默病和神经炎症的当前科学文献的综述.
- 对Aβ物种微质激活机制的分析.
- 讨论人类微质的转录变化和异质性.
主要成果:
- 微质细胞,大脑的免疫细胞,检测并被Aβ物种激活.
- 激活的微质细胞对阿尔茨海默病的发病有显著的贡献.
- 周围信号和其他细胞类型也在AD的免疫激活中发挥作用.
结论:
- 免疫激活,特别是微质细胞的激活,是阿尔茨海默病发展的关键组成部分.
- 对微质异质性和外围免疫贡献的进一步研究是必不可少的.
- 准免疫路径为阿尔茨海默病提供了一个有希望的治疗途径.
相关概念视频
01:26Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
01:22Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188